A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis

NCT00888745 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2010-12-01

No results posted yet for this study

Summary

This is a Phase I multicenter study that will be conducted in the United States and Europe.

Conditions

Interventions

DRUG

placebo

Intravenous and subcutaneous ascending dose

DRUG

PRO283698

Intravenous and subcutaneous ascending dose

Sponsors & Collaborators

  • Genentech, Inc.

    lead INDUSTRY

Principal Investigators

  • June Lee, M.D. · Genentech, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2010-06-30

Countries

  • United States
  • Hungary

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00888745 on ClinicalTrials.gov